This Moment Calls for Firm Discipline<br />By Rev Shark<br />RealMoney.com Contributor<br />6/17/2009 8:42 AM EDT<br /><br /> Discipline is the bridge between goals and accomplishments.<br /> -- Jim Rohn<br /><br />One of the hardest things to do in the market is to determine whether a pullback after a big move is just a good buying opportunity or the beginning of a change in trend. If we are correct about a pullback just being a dip, we can buy into the weakness and make some good profits, but if we are wrong and find ourselves stuck in a market that is rolling over and changing trend, the losses can mount quickly. Unfortunately, there is no way we'll ever know for sure which approach will prove to be the right one until after the fact.<br /><br />The key to dealing with this dilemma is to have a disciplined money management approach. Even if you believe we are seeing nothing more than a temporary dip, you still need to have a line in the sand where you take losses just in case you are wrong. One of the very frustrating things about disciplined money management is that no matter how smart you might be, you will invariably be stopped out of positions only to see them immediately reverse back up.<br /><br />No money management system is going to deliver perfect results, but that isn't their primary function. The key function of money management is to reduce your risk of big losses should the market not act the way you hope it will. You have to pay a price for that insurance, and that price is that you will sell some stocks at less-than-optimal levels.<br /><br />We are at a market juncture right now where it is extremely important to be disciplined. For more than three months, the market has made fools of anyone who thought that we were just seeing a bear-market rally that would soon fizzle. Time and again we have barely dipped before continuing higher. With that pattern in mind, there is going to be a strong inclination to give positions more room so you aren't left out when things turn back up again.<br /><br />We may indeed reverse and go straight back up (just like we did in May) after a few days of weakness similar to what we are seeing right now. We have broken some important technical support and the momentum action has turned poor, but we haven't see any really panicky action like we did back in January and February.<br /><br />The important thing is to control your risk and not let your hope that the bear market is over keep you from making moves to limit losses. Yes, you might end up selling at just the wrong time if you set stops too tight, but you can always buy positions back. A lot of folks have a mental block about buying something back that they just sold, but it can be very good strategy. Just think of it as paying an insurance premium.<br /><br />After two days of weak action, the market is probably due for a relief bounce. The key will be whether the buyers can generate the same vigor they have had so often when they have come roaring back and run over any bears. It is looking like the dip-buyers may be losing some energy, but they haven't been tested yet. Be tough with your trading discipline and don't let losses grow if things don't work the way you think they will.<br /><br />We have a minor positive start on the way. I see some good analyst upgrades, but guidance from FedEx (FDX) is worrisome. <br />----------------------------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: SMG +4.9%, SLAB +4.2$... Select European drug related names showing strength: SNY +2.8%, AZN +1.3%... Other news: MIPI +29.2% (presents clinical data on prostate cancer diagnostic; demonstrates potential to rapidly detect prostate cancer), SVNT +27.6% (confirms FDA appointed arthritis advisory committee recommends U.S. FDA approval for KRYSTEXXA for refractory chronic gout; also upgraded to Outperform from Neutral at Cowen and upgraded to Perform at Oppenheimer), AGEN +18.6% (Antigenics QS-21 Adjuvant enters pivotal phase 3 clinical trial of GlaxoSmithKline's malaria vaccine), NBIX +11.0% (presents Elagolix data; no long-term bone risk during or after treatment), ALVR +7.2% (Alvarion and Open Range sign a multi-year contract for equipment and services expected at over $100 mln for 4G network across 17 states), EIG +4.3% (will replace Catapult Communications in the S&P SmallCap 600), GWR +3.3% (prices 4.0 mln common share offering at $24.50/share), LNC +2.7% (prices 40.0 mln common share offering at $15.00/share), RAI +2.4% (Jury rules in favor of R.J. Reynolds Tobacco Company in patent suit), MYL +1.4% (receives FDA approval for additional strength of generic restoril)... Analyst comments: TNDM +3.9% (upgraded to Outperform at Baird), NFLX +3.6% (May website traffic suggests Netflix could top its 2Q09 subscriber guidance - Lazard Capital Mkts), TXN +3.2% ( upgraded to Buy from Underperform at BofA/Merrill), QCOM +2.0% (upgraded to Conviction Buy from Neutral; price target to $53 from $43 at Goldman- Reuters).<br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: RVI -5.1% (light volume), FDX -2.7%, ADBE -2.1%... Select financial names showing weakness: AIB -9.5%, IRE -4.7%, ING -4.1%, RBS -1.0% (Royal Bank of Scotland chief warns about higher property losses- FT.com)... Select potash stocks trading lower following K+S warning on weak European demand: POT -3.0%, MOS -2.9%, IPI -2.9%, CF -2.2%, AGU -2.1%, SQM -2.0%, SYT -1.8%... Select metals/mining names showing weakness: RTP -5.3% (receives China "monopoly" challenge - Times Online), MT -3.7%, GOLD -3.7%, AAUK -2.8%, GOLD -2.5% (downgraded to Sector Perform from Outperform at RBC Capital), SLW -2.5%, BBL -1.6%... Other news: STSI -72.2% (confirms jury verdict announced in Star Scientific patent infringement lawsuit against RJ Reynolds), ETFC -15.2% (reports May DARTS increased 4% MoM and 34% YoY; also announces $1.2 bln plan to strengthen capital structure; includes common equity offering, debt exchange transactions), JAZZ -5.0% (still checking), WLL -4.0% (announces public offering of 3,000,000 shares convertible perpetual preferred stock), MTXX -2.9% (confirms it is voluntarily withdrawing Zicam Cold Remedy Swabs and Zicam Cold Remedy Gel from the market), WPI -2.0% (to Acquire Arrow Group for $1.75 bln; expected to be accretive to EPS in 2010), TRP -2.0% (to issue 50,800,000 common shares at C$31.50/share and agrees to become the sole owner of the Keystone Pipeline System)... Analyst comments: PKG -3.4% (downgraded to Underweight at JPMorgan), COMS -2.5% (downgraded to Market Perform from Outperform at Bernstein), PCL -2.0% (downgraded to Underweight at JPMorgan), UL -1.3% (downgraded to Sell at UBS).